Huiyu Pharmaceutical(SH:688553) Zheng Quan Ri Bao·2026-01-28 11:44Group 1 - The core announcement is that Huayu Pharmaceutical's wholly-owned subsidiary, Sichuan Huayu Haiyue Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of the innovative chemical drug HYP-6589 tablets, which is intended for use in combination with Osimertinib for treating advanced non-small cell lung cancer with target-driven gene positivity [2] Group 2 - The clinical trial approval is a significant step for the company in advancing its research and development efforts in oncology [2] - HYP-6589, also referred to by its research and development code "HY-0006," represents a potential new treatment option in the competitive oncology market [2] - The approval highlights the company's commitment to developing innovative therapies for serious health conditions [2]